Presymptomatic studies in ALS: Rationale, challenges, and approach
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
It is now well-established that the disease process in many neurodegenerative disorders, including Alzheimer disease, Parkinson disease, and Huntington disease, begins many years before the appearance of typical symptoms.Whether amyotrophic lateral sclerosis (ALS) is also characterized by a presymptomatic period, and if so how long this period lasts, is unclear.Answers to these questions will not only inform our understanding of disease biology and potential environmental risk factors for ALS, but also the design and implementation of early therapeutic and even preventative clinical trials.Moreover, the potential impact of studying people at genetic risk for ALS, the only population in which it is currently possible to study presymptomatic disease, is underscored by recent progress in our understanding of the shared genetic basis of familial and apparently sporadic ALS.Studying presymptomatic ALS, however, has proven difficult due to the challenge in identifying an at-risk population and various logistical and ethical considerations.In this article we present the rationale for studying presymptomatic ALS, summarize the early evidence supporting the existence of a presymptomatic phase of the disease, and discuss the challenges of studying presymptomatic ALS.We also use Pre-fALS a systematic and longitudinal investigation of a cohort of individuals at genetic risk for ALS, as an example to illustrate how one might approach these challenges.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
DeJesus-Hernandez, M., Mackenzie, I. R., Boeve, B. F., Boxer, A. L., Baker, M., Rutherford, N. J., Nicholson, A. M., Finch, N. A., Flynn, H., Adamson, J., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.09.011 · Cited by 4,936
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
A Hexanucleotide Repeat Expansion in C9ORF72 Is the Cause of Chromosome 9p21-Linked ALS-FTD
Renton, A. E., Majounie, E., Waite, A., Simón-Sánchez, J., Rollinson, S., Gibbs, J. R., Schymick, J. C., Laaksovirta, H., van Swieten, J. C., Myllykangas, L., et al. (2011) · Neuron · doi:10.1016/j.neuron.2011.09.010 · Cited by 4,409
Self-citationExome Sequencing Reveals VCP Mutations as a Cause of Familial ALS
Johnson, J. O., Mandrioli, J., Benatar, M., Abramzon, Y., Van Deerlin, V. M., Trojanowski, J. Q., Gibbs, J. R., Brunetti, M., Gronka, S., Wuu, J., et al. (2010) · Neuron · doi:10.1016/j.neuron.2010.11.036 · Cited by 1,235
Self-citationMutations in UBQLN2 cause dominant X-linked juvenile and adult-onset ALS and ALS/dementia
Deng, H.-X., Chen, W., Hong, S.-T., Boycott, K. M., Gorrie, G. H., Siddique, N., Yang, Y., Fecto, F., Shi, Y., Zhai, H., et al. (2011) · Nature · doi:10.1038/nature10353 · Cited by 1,174
Incidence of amyotrophic lateral sclerosis in Europe
Logroscino, G., Traynor, B. J., Hardiman, O., Chio, A., Mitchell, D., Swingler, R. J., Millul, A., Benn, E., Beghi, E., & EURALS, F. (2010) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2009.183525 · Cited by 772
Van Deerlin, V. M., Leverenz, J. B., Bekris, L. M., Bird, T. D., Yuan, W., Elman, L. B., Clay, D., Wood, E. M., Chen-Plotkin, A. S., Martinez-Lage, M., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70071-1 · Cited by 723
Epidemiology and clinical features of amyotrophic lateral sclerosis in Ireland between 1995 and 2004
O'Toole, O., Traynor, B. J., Brennan, P., Sheehan, C., Frost, E., Corr, B., & Hardiman, O. (2008) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2007.117788 · Cited by 197
Cited by
De Vivo, D. C., Bertini, E., Swoboda, K. J., Hwu, W.-L., Crawford, T. O., Finkel, R. S., Kirschner, J., Kuntz, N. L., Parsons, J. A., Ryan, M. M., et al. (2019) · Neuromuscular Disorders · doi:10.1016/j.nmd.2019.09.007 · Cited by 629
Controversies and priorities in amyotrophic lateral sclerosis
Turner, M. R., Hardiman, O., Benatar, M., Brooks, B. R., Chio, A., de Carvalho, M., Ince, P. G., Lin, C., Miller, R. G., Mitsumoto, H., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70036-x · Cited by 541
Self-citationBenatar, M., Wuu, J., Andersen, P. M., Lombardi, V., & Malaspina, A. (2018) · Annals of Neurology · doi:10.1002/ana.25276 · Cited by 297
Self-citationNeurofilament light chain: a biomarker for genetic frontotemporal dementia
Meeter, L. H., Dopper, E. G., Jiskoot, L. C., Sanchez‐Valle, R., Graff, C., Benussi, L., Ghidoni, R., Pijnenburg, Y. A., Borroni, B., Galimberti, D., et al. (2016) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.325 · Cited by 263
Menke, R. A. L., Körner, S., Filippini, N., Douaud, G., Knight, S., Talbot, K., & Turner, M. R. (2014) · Brain · doi:10.1093/brain/awu162 · Cited by 189
Metadata
- Authors
- Benatar, M., & Wuu, J.
- Venue
- Neurology
- Published
- 2012-10-16
- Volume
- 79
- Issue
- 16
- Pages
- 1732-1739
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W1995627787
- Cited by
- 122
- References
- 8
- FWCI
- 4.30
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Presymptomatic studies in ALS: Rationale, challenges, and approach. https://app.cochat.ai/papers/10.1212/wnl.0b013e31826e9b1d
- The paper
- Benatar, M., & Wuu, J. (2012). Presymptomatic studies in ALS: Rationale, challenges, and approach. Neurology. https://doi.org/10.1212/wnl.0b013e31826e9b1d
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.